Skip to main content

Drug Interactions between dabigatran and pitolisant

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

dabigatran pitolisant

Applies to: dabigatran and pitolisant

GENERALLY AVOID: Coadministration with inducers of P-glycoprotein (P-gp) may significantly reduce the bioavailability of dabigatran following oral administration of dabigatran etexilate, which is a substrate of the efflux transporter. When a single dose of dabigatran etexilate was administered following pretreatment with the P-gp inducer rifampin (600 mg once daily for 7 days), dabigatran peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by approximately two-thirds compared to the reference treatment. Dabigatran exposure was close to normal seven days after cessation of rifampin.

MANAGEMENT: Concomitant use of dabigatran with P-gp inducers should generally be avoided.

References (5)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Cerner Multum, Inc. "Australian Product Information."
  3. (2008) "Product Information. Pradax (dabigatran)." Boehringer Ingelheim (Canada) Ltd
  4. (2010) "Product Information. Pradaxa (dabigatran)." Boehringer-Ingelheim
  5. Randhawa J, Thiruchelvam N, Ghobrial M, et al. (2014) "Practical recommendations on incorporating new oral anticoagulants into routine practice." Clin Adv Hematol Oncol, 12, p. 675-83

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer